vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Envela Corp (ELA). Click either name above to swap in a different company.
Envela Corp is the larger business by last-quarter revenue ($80.5M vs $62.1M, roughly 1.3× Cytek Biosciences, Inc.). Envela Corp runs the higher net margin — 7.4% vs -70.9%, a 78.4% gap on every dollar of revenue. On growth, Envela Corp posted the faster year-over-year revenue change (66.6% vs 8.1%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.7M). Over the past eight quarters, Envela Corp's revenue compounded faster (42.1% CAGR vs 17.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.
CTKB vs ELA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $80.5M |
| Net Profit | $-44.1M | $6.0M |
| Gross Margin | 52.9% | 20.5% |
| Operating Margin | -9.0% | 9.4% |
| Net Margin | -70.9% | 7.4% |
| Revenue YoY | 8.1% | 66.6% |
| Net Profit YoY | -557.1% | 274.6% |
| EPS (diluted) | — | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $80.5M | ||
| Q3 25 | $52.3M | $57.4M | ||
| Q2 25 | $45.6M | $54.9M | ||
| Q1 25 | $41.5M | $48.3M | ||
| Q4 24 | $57.5M | $48.3M | ||
| Q3 24 | $51.5M | $46.9M | ||
| Q2 24 | $46.6M | $45.3M | ||
| Q1 24 | $44.9M | $39.9M |
| Q4 25 | $-44.1M | $6.0M | ||
| Q3 25 | $-5.5M | $3.4M | ||
| Q2 25 | $-5.6M | $2.8M | ||
| Q1 25 | $-11.4M | $2.5M | ||
| Q4 24 | $9.6M | $1.6M | ||
| Q3 24 | $941.0K | $1.7M | ||
| Q2 24 | $-10.4M | $1.6M | ||
| Q1 24 | $-6.2M | $1.9M |
| Q4 25 | 52.9% | 20.5% | ||
| Q3 25 | 52.7% | 22.8% | ||
| Q2 25 | 52.3% | 22.6% | ||
| Q1 25 | 48.6% | 24.8% | ||
| Q4 24 | 58.5% | 23.1% | ||
| Q3 24 | 56.3% | 24.4% | ||
| Q2 24 | 54.6% | 25.1% | ||
| Q1 24 | 51.3% | 25.9% |
| Q4 25 | -9.0% | 9.4% | ||
| Q3 25 | -17.6% | 7.3% | ||
| Q2 25 | -23.3% | 5.9% | ||
| Q1 25 | -36.1% | 6.5% | ||
| Q4 24 | 5.2% | 3.9% | ||
| Q3 24 | -8.2% | 4.3% | ||
| Q2 24 | -18.3% | 4.2% | ||
| Q1 24 | -23.9% | 5.9% |
| Q4 25 | -70.9% | 7.4% | ||
| Q3 25 | -10.5% | 5.8% | ||
| Q2 25 | -12.2% | 5.0% | ||
| Q1 25 | -27.5% | 5.2% | ||
| Q4 24 | 16.8% | 3.3% | ||
| Q3 24 | 1.8% | 3.6% | ||
| Q2 24 | -22.4% | 3.5% | ||
| Q1 24 | -13.8% | 4.8% |
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.13 | ||
| Q2 25 | — | $0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | — |
| Total DebtLower is stronger | — | $9.9M |
| Stockholders' EquityBook value | $341.7M | $67.1M |
| Total Assets | $461.5M | $96.0M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | — | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | — | ||
| Q3 24 | $162.3M | — | ||
| Q2 24 | $177.9M | — | ||
| Q1 24 | $168.8M | $19.8M |
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.2M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $13.8M | ||
| Q2 24 | — | $14.3M | ||
| Q1 24 | — | $14.6M |
| Q4 25 | $341.7M | $67.1M | ||
| Q3 25 | $378.6M | $61.1M | ||
| Q2 25 | $377.6M | $57.8M | ||
| Q1 25 | $379.6M | $55.1M | ||
| Q4 24 | $395.7M | $52.7M | ||
| Q3 24 | $385.5M | $51.1M | ||
| Q2 24 | $389.1M | $50.2M | ||
| Q1 24 | $392.6M | $49.3M |
| Q4 25 | $461.5M | $96.0M | ||
| Q3 25 | $494.9M | $90.9M | ||
| Q2 25 | $493.3M | $82.7M | ||
| Q1 25 | $482.6M | $79.7M | ||
| Q4 24 | $499.5M | $77.9M | ||
| Q3 24 | $491.2M | $77.4M | ||
| Q2 24 | $483.7M | $73.8M | ||
| Q1 24 | $492.1M | $74.7M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-3.5M |
| Free Cash FlowOCF − Capex | $-1.8M | $-3.7M |
| FCF MarginFCF / Revenue | -2.9% | -4.6% |
| Capex IntensityCapex / Revenue | 1.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $1.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-3.5M | ||
| Q3 25 | $-3.9M | $2.4M | ||
| Q2 25 | $108.0K | $2.6M | ||
| Q1 25 | $-125.0K | $1.1M | ||
| Q4 24 | $2.0M | $3.7M | ||
| Q3 24 | $13.2M | $3.4M | ||
| Q2 24 | $6.2M | $-789.5K | ||
| Q1 24 | $4.0M | $3.8M |
| Q4 25 | $-1.8M | $-3.7M | ||
| Q3 25 | $-4.6M | $2.2M | ||
| Q2 25 | $-1.5M | $2.1M | ||
| Q1 25 | $-974.0K | $746.6K | ||
| Q4 24 | $1.1M | $3.2M | ||
| Q3 24 | $12.2M | $1.5M | ||
| Q2 24 | $5.2M | $-1.3M | ||
| Q1 24 | $3.4M | $3.3M |
| Q4 25 | -2.9% | -4.6% | ||
| Q3 25 | -8.7% | 3.8% | ||
| Q2 25 | -3.2% | 3.9% | ||
| Q1 25 | -2.3% | 1.5% | ||
| Q4 24 | 1.9% | 6.7% | ||
| Q3 24 | 23.7% | 3.1% | ||
| Q2 24 | 11.0% | -2.9% | ||
| Q1 24 | 7.6% | 8.4% |
| Q4 25 | 1.6% | 0.2% | ||
| Q3 25 | 1.3% | 0.4% | ||
| Q2 25 | 3.5% | 0.8% | ||
| Q1 25 | 2.0% | 0.8% | ||
| Q4 24 | 1.6% | 1.0% | ||
| Q3 24 | 2.0% | 4.2% | ||
| Q2 24 | 2.3% | 1.1% | ||
| Q1 24 | 1.3% | 1.1% |
| Q4 25 | — | -0.59× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | 0.21× | 2.34× | ||
| Q3 24 | 14.05× | 2.05× | ||
| Q2 24 | — | -0.50× | ||
| Q1 24 | — | 1.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
